Ideaya Biosciences, Inc. (IDYA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$39.86-0.28%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IDYA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete NDA filing for darovasertib combination in metastatic uveal melanoma and progress clinical trials including registrational and adjuvant settings.
Stated as a priority in 2 of last 2 quarters. The registrational OptimUM-02 trial met its primary endpoint with median progression-free survival of 6.9 months versus 3.1 months in control. NDA filing is underway targeting completion in H2 2026. The trajectory matches management's stated timeline and clinical progress, delivering on the NDA submission milestone.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Registrational OptimUM-02 trial met its primary endpoint; NDA filing underway under RTOR program with completion expected in H2 2026.”
“Positive topline results from OptimUM-02 trial enable first NDA submission; targeting completion in H2 2026.”
Initiate Phase 1 combination trial of IDE892 with Roche's RG6505 in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma in H2 2026.
Stated as a priority in 2 of last 2 quarters. Management announced a clinical collaboration with Roche to initiate a Phase 1 combination trial of IDE892 with RG6505 in MTAP-deleted, RAS-mutant pancreatic cancer in the second half of 2026. This is a new strategic collaboration with planned trial initiation consistent with management's timeline, indicating delivery on this growth priority.
“Announced clinical collaboration with Roche to evaluate IDE892 with RG6505 in MTAP-deleted RAS-mutant pancreatic cancer; Phase 1 trial targeted in H2 2026.”
“Planning Phase 1 combination cohort of IDE892 with IDE397 in MTAP-deleted cancers mid-2026; collaboration with Roche announced for PDAC combination trial.”
Grow collaboration revenue and advance clinical programs to support future commercial opportunities.
Stated as a priority in 2 of last 2 quarters. Collaboration revenue grew from $6.6 million in 2026-Q1 to $8.9 million in 2026-Q2, reflecting progress in clinical development collaborations, notably under the Servier license agreement for darovasertib. The revenue trajectory shows growth consistent with management's stated focus on collaboration-driven revenue expansion.
“Collaboration revenue for Q2 2026 totaled $8.9 million, up from $6.6 million in Q1 2026.”
“Collaboration revenue for Q1 2026 totaled $6.6 million, recognized under Servier exclusive license agreement.”
Preserve financial resources to support operations and clinical development through 2030 based on current operating plan.
Stated as a priority in 2 of last 2 quarters. Cash and equivalents increased from approximately $972.9 million in 2026-Q1 to $1.24 billion in 2026-Q2, supported by a public offering. Management reiterated the cash runway guidance into 2030 remains unchanged based on the current operating plan. The financial position and guidance confirm delivery on maintaining cash runway.
“Cash runway guidance into 2030 is unchanged based on current operating plan; cash and equivalents approx. $1.24 billion as of June 30, 2026.”
“Current cash runway guidance into 2030 remains unchanged; cash and equivalents approx. $972.9 million as of March 31, 2026.”
Control operating expenses while advancing clinical programs to improve operating income over time.
Stated as a priority in 2 of last 2 quarters. Operating expenses increased from $115.1 million in 2026-Q1 to $131.1 million in 2026-Q2 driven by higher clinical trial and personnel costs. Net loss increased from $98.5 million to $112.5 million over the same period. The trajectory shows increased expenses consistent with advancing clinical programs, indicating limited progress on improving operating income so far.
“Operating expenses totaled $131.1 million in Q2 2026, up from $115.1 million in Q1 2026 due to higher clinical trial and personnel expenses.”
“Operating expenses were $115.1 million in Q1 2026, increased from prior periods reflecting clinical and personnel costs.”
Over the trailing year it converted 0.83x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
15 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.